Assenagon Asset Management
GYRE icon

Assenagon Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Assenagon Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-68,352
Closed -$469K – 1477
2021
Q4 		$469K Buy
+68,352
New +$1.17M ﹤0.01% 1206
2020
Q3 		– Sell
-20,181
Closed -$888K – 1218
2020
Q2 		$888K Buy
+20,181
New +$948K 0.01% 835
2019
Q2 		– Sell
-38,480
Closed -$2.34M – 1055
2019
Q1 		$2.34M Buy
38,480
+11,160
+41% +$717K 0.02% 474
2018
Q4 		$1.62M Buy
+27,320
New +$2.01M 0.02% 516

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Assenagon Asset Management's GYRE Position: Q1 2022 in Review

Assenagon Asset Management sold out of Gyre Therapeutics (GYRE) in Q1 2022, closing a stake of 68,352 shares — an estimated $469K sold.

Assenagon Asset Management first reported a position in GYRE in Q4 2018 and held it in 4 quarters. The position peaked at $2.34M in Q1 2019. 43 funds tracked by Wall St. Rank hold GYRE as of Q1 2022.

  • Assenagon Asset Management reported no remaining Gyre Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Assenagon Asset Management sold 68,352 Gyre Therapeutics shares in Q1 2022, an estimated $469K.
  • Assenagon Asset Management first reported a position in Gyre Therapeutics in Q4 2018 and held it in 4 quarters.
  • Assenagon Asset Management's Gyre Therapeutics position peaked at $2.34M in Q1 2019.
  • 43 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2022.

Based on Assenagon Asset Management's 13F filing for Q1 2022, filed 25 Apr 2022.